Retatrutide TRIUMPH-9: A New Phase 3 Trial Testing Dose-Escalation Design
TL;DR: New ClinicalTrials.gov listing NCT07357415 ("TRIUMPH-9") tests retatrutide dose-escalation regimens in ~600 adults with obesity, no T2D.
What Is TRIUMPH-9, and What Is It Testing?
A new entry has appeared in Eli Lilly's retatrutide (LY3437943) Phase 3 programme: ClinicalTrials.gov registration NCT07357415, officially titled "A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight."[1] Trial-tracking sites have informally labelled it TRIUMPH-9, consistent with its place in Lilly's registrational trial numbering alongside TRIUMPH-1 through TRIUMPH-4.[2]
What sets this listing apart from earlier TRIUMPH studies is its stated design intent. TRIUMPH-1 and TRIUMPH-4 both randomised participants to fixed 4 mg, 9 mg or 12 mg maintenance doses, each reached through the same single titration schedule.[3] TRIUMPH-9's registry summary instead describes an evaluation of different methods of escalating the dose to a maintenance level, rather than a comparison of different maintenance doses themselves. In other words, this trial is examining the on-ramp, not the destination.
Why Does a Dose-Escalation Schedule Matter for Retatrutide's Phase 3 Data?
Titration speed is a well-established lever that Phase 3 sponsors adjust independently of target dose. Faster escalation shortens time-to-therapeutic-dose but tends to raise rates of gastrointestinal adverse events and discontinuation; slower escalation generally improves tolerability at the cost of a longer run-in period. Across the GLP-1/GIP/glucagon receptor-agonist class, titration-schedule optimisation has repeatedly been the subject of dedicated trial arms and label updates.
The question carries particular weight for retatrutide because two tolerability and safety signals are already on the public record from earlier in its Phase 3 programme. Our coverage of TRIUMPH-4 details a dysesthesia finding presented at ADA 2026 — 20.9% of participants on the 12 mg dose reported dysesthesia versus 0.7% on placebo, a signal not reported for tirzepatide or semaglutide.[4] Separately, our coverage of TRANSCEND-T2D-1 notes an arrhythmia imbalance (7 of 403 retatrutide participants versus 0 of 134 on placebo).[5] Neither finding is confirmed to be dose- or titration-related, and ClinicalTrials.gov does not publish a stated rationale for TRIUMPH-9. But the existence of a dedicated escalation-design trial running concurrently with these open safety questions is a relevant data point for researchers tracking the compound's evidence base — not a causal claim this article is making on Lilly's behalf.
How Does TRIUMPH-9's Design Differ From the Schedule Used in TRIUMPH-1?
The registrational-trial design paper for TRIUMPH-1 through TRIUMPH-4 describes a fixed dose-escalation sequence used to reach each maintenance dose: 2 mg (weeks 1–4), 4 mg (weeks 5–8), 6 mg (weeks 9–12), 9 mg (weeks 13–16), stepping to 12 mg from week 17 for participants randomised to the top dose.[6] This single schedule applied across all dose arms in those trials — it was not itself a variable being tested.
Source: Giblin K, et al. Diabetes, Obesity and Metabolism, 2026;28(1):83–93. PMID: 41090431
TRIUMPH-9's registry entry, by contrast, is built to compare escalation approaches directly. The publicly available summary does not break out the exact number of arms or the specific alternative schedules under test, and Velox has not been able to independently verify those details against the full protocol document, which is not public. Readers who want the primary source should consult the registration directly rather than relying on secondary trial-tracker paraphrases, which vary slightly in how they describe the comparison.
Who Is Eligible, and How Large Is the Trial?
Eligibility: Adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related condition such as hypertension, dyslipidaemia or obstructive sleep apnoea. Participants with type 2 diabetes are excluded — a narrower population than TRIUMPH-2, which specifically enrols people who have both obesity and type 2 diabetes.[7] Anyone who used a weight-management medication in the 90 days before screening is also excluded.
Scale and duration: Estimated enrolment of roughly 600 participants across an approximately 113-week study, broadly in line with the duration of TRIUMPH-3. The trial was reported as actively enrolling at Lilly sites by April 2026.
Source: ClinicalTrials.gov NCT07357415
What Does TRIUMPH-9 Mean for Retatrutide's FDA Approval Timeline?
Not much in the near term. As our FDA approval timeline guide covers, Eli Lilly's targeted Q4 2026 NDA submission is built on the already-reported TRIUMPH-1, TRIUMPH-4 and TRANSCEND-T2D-1 datasets, alongside whatever TRIUMPH-2 and TRIUMPH-3 add before filing closes. TRIUMPH-9's roughly 113-week duration, combined with its later appearance in the registry, makes it very unlikely to read out in time to inform that initial filing package.
A more plausible role is a later label refinement — supporting a revised or alternative titration schedule after an initial approval, similar to how other GLP-1-class products have added or adjusted dose-titration options post-launch. That remains an inference based on the trial's design and timing, not a confirmed plan; Eli Lilly has not published a stated purpose for TRIUMPH-9 alongside the registration.
What Should UK Researchers Take From This?
Nothing about TRIUMPH-9 changes retatrutide's UK regulatory status: it remains an unlicensed, investigational compound with no MHRA marketing authorisation, and nothing in this trial-tracking summary constitutes a therapeutic or health claim. For researchers following the compound's evidence base, TRIUMPH-9 is best read as a signal that Eli Lilly considers dose-escalation design an open, still-optimisable variable in retatrutide's clinical development — worth tracking alongside the pending TRIUMPH-2 and TRIUMPH-3 readouts, not a standalone efficacy or safety result in itself. Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent, with no health or therapeutic claims made for it.
This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight. NCT07357415
- CenterWatch. Clinical trial listing summary for NCT07357415 ("TRIUMPH-9"). centerwatch.com
- Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism, 2026;28(1):83–93. PMID: 41090431
- Presented at ADA 86th Scientific Sessions, 6 June 2026. See Velox coverage: Retatrutide Dysesthesia: TRIUMPH-4 Safety Signal
- Bajaj HS, et al. TRANSCEND-T2D-1, The Lancet, 2026. PMID: 42250575. See Velox coverage: Retatrutide Arrhythmia Signal
- Giblin K, et al. Diabetes, Obesity and Metabolism, 2026;28(1):83–93 (escalation schedule as reported in trial design). PMID: 41090431
- ClinicalTrials.gov. A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2). NCT05929079
Frequently Asked Questions
What is TRIUMPH-9, and what is it testing?
TRIUMPH-9 is the informal industry name for ClinicalTrials.gov registration NCT07357415, officially titled "A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight." Unlike TRIUMPH-1 and TRIUMPH-4, which tested fixed 4 mg, 9 mg and 12 mg maintenance doses reached via a single titration schedule, the registry listing indicates TRIUMPH-9 compares different methods of escalating the dose rather than testing a new target dose.
Why would a dose-escalation schedule need its own Phase 3 trial?
Titration speed is a standard variable that Phase 3 sponsors adjust to manage gastrointestinal tolerability and discontinuation rates without changing the eventual target dose. It is a relevant open question for retatrutide specifically because TRIUMPH-4 already reported a dysesthesia signal (20.9% of 12 mg participants versus 0.7% on placebo) and TRANSCEND-T2D-1 reported a cardiac arrhythmia imbalance — both signals that a sponsor could reasonably want to characterise against different escalation approaches. ClinicalTrials.gov does not publish a stated rationale, so this is analytical context, not a confirmed motive from Eli Lilly.
Who is eligible for TRIUMPH-9 and how large is it?
Trial-registry trackers list an estimated enrolment of roughly 600 adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with a weight-related condition such as hypertension, dyslipidaemia or obstructive sleep apnoea. Participants with type 2 diabetes are excluded, as are those who used a weight-management medication in the 90 days before screening. The study duration is listed at approximately 113 weeks, and the trial was reported as actively enrolling at Lilly sites by April 2026.
Will TRIUMPH-9 affect retatrutide's FDA approval timeline?
Not directly. Eli Lilly's targeted Q4 2026 NDA submission is built on the already-reported TRIUMPH-1, TRIUMPH-4 and TRANSCEND-T2D-1 datasets. TRIUMPH-9's roughly 113-week duration and later registry appearance make it unlikely to read out in time to inform that initial filing; it more plausibly feeds a future label refinement on dosing or a post-approval titration option, though Eli Lilly has not published a stated purpose.
Is retatrutide legal to buy in the UK for research?
Yes. Retatrutide is legal to purchase in the UK for in vitro research purposes. It is not licensed as a medicine and is not approved for human use anywhere. Velox Peptides supplies retatrutide strictly as a research reagent in accordance with its Research Use Policy.